Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10033MR)

This product GTTS-WQ10033MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10033MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2637MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ9434MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ13402MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ9325MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ3766MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ11946MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ10232MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ11377MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-573
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW